Why the study?
While DAPT is standard of care for ACS and secondary prevention of CAD, determining optimal treatment duration and composition remains a major challenge.
The optimal treatment duration and composition of dual antiplatelet therapy in patients with ACS or CAD remains a major clinical challenge.
DAPT optimization in ACS/CAD remains challenging; leaves open duration and composition questions for future trials.
Dual antiplatelet therapy (DAPT) is the evidence-based standard of care in patients with acute coronary syndrome (ACS) managed invasively or noninvasively, as well as for secondary prevention of coronary artery disease (CAD). The optimal treatment duration and composition of DAPT, however, remains a major challenge.
No takes yet. Share an insight, caveat, or question.
Jurisic et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: